Implications of neuroendocrine tumor and diabetes mellitus on patient outcomes and care: a matched case-control study.

Autor: Kusne YN; Department of Internal Medicine, Mayo Clinic, Scottsdale 85259, Arizona., Kosiorek HE; Biostatistics, Mayo Clinic, Scottsdale 85259, Arizona., Buras MR; Biostatistics, Mayo Clinic, Scottsdale 85259, Arizona., Verona PM; Enterprise Technology Services, Mayo Clinic, Scottsdale 85259, Arizona., Coppola KE; Mayo Clinic Cancer Center, Mayo Clinic, Scottsdale 85259, Arizona., Rone KA; Division of Hematology & Medical Oncology, Mayo Clinic Hospital, Phoenix 85054, Arizona., Cook CB; Division of Endocrinology, Mayo Clinic, Scottsdale 85259, Arizona., Karlin NJ; Mayo Clinic Cancer Center, Mayo Clinic, Scottsdale 85259, Arizona.; Division of Hematology & Medical Oncology, Mayo Clinic Hospital, Phoenix 85054, Arizona.
Jazyk: angličtina
Zdroj: Future science OA [Future Sci OA] 2021 Feb 15; Vol. 7 (5), pp. FSO684. Date of Electronic Publication: 2021 Feb 15.
DOI: 10.2144/fsoa-2020-0190
Abstrakt: Aim: We aimed to determine the impact of diabetes mellitus (DM) on survival of patients with neuroendocrine tumors (NETs) and of NETs on glycemic control.
Patients & Methods: Patients with newly diagnosed NETs with/without DM were matched 1:1 by age, sex and diagnosis year (2005-2017), and survival compared (Kaplan-Meier and Cox proportional hazards). Mixed models compared hemoglobin A 1c (HbA 1c ) and glucose during the year after cancer diagnosis.
Results: Three-year overall survival was 72% (95% CI: 60-86%) for DM patients versus 80% (95% CI: 70-92%) for non-DM patients (p = 0.82). Hazard ratio was 1.33 (95% CI: 0.56-3.16; p = 0.51); mean DM HbA 1c , 7.3%.
Conclusion: DM did not adversely affect survival of patients with NET. NET and its treatment did not affect glycemic control.
Competing Interests: Financial & competing interests disclosure The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties. No writing assistance was utilized in the production of this manuscript.
(© 2021 Mayo Foundation for Medical Education and Research.)
Databáze: MEDLINE
Externí odkaz: